Research Topics
Species | Young Hak KimSummaryAffiliation: Kyoto University Country: Japan Publications
| Collaborators
|
Detail Information
Publications
Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancerYoung Hak Kim
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto, Japan
Clin Lung Cancer 13:385-90. 2012..The activities of IGF are strictly regulated by a family of IGF binding proteins (IGFBP), especially IGFBP3, a major serum carrier protein for IGF...- Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902Young Hak Kim
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto 606 8507, Japan
Cancer Chemother Pharmacol 70:271-6. 2012.... 
Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST)Shiro Tanaka
Department of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyoku, Kyoto 606 8507, Japan
Trials 12:120. 2011..We are conducting a single arm phase II trial which aims to evaluate the efficacy and safety of this regime as a second- or third-line chemotherapy...- Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapyShiro Fujita
Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2 2 Minatojima Minami machi, Chuo Ku, Kobe, Japan
BMC Med Genet 11:167. 2010..The aim of this study was to evaluate the influence of polymorphisms in the eNOS gene on prognosis of patients with advanced stage non-small-cell lung cancer (NSCLC)... - Maintenance chemotherapy for non-small-cell lung cancerYoung Hak Kim
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
Cancer Treat Rev 37:505-10. 2011..In this review, we summarize the major clinical trials of maintenance chemotherapy in patients with NSCLC, and discuss its clinical validity and present future perspectives... - Second-line chemotherapy for small-cell lung cancer (SCLC)Young Hak Kim
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
Cancer Treat Rev 37:143-50. 2011..Unfortunately, targeted agents have failed to demonstrate effectiveness for SCLC. Better understanding of the molecular mechanisms is clearly needed... - Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancerYoung Hak Kim
Division of Thoracic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
Respir Med 104:434-9. 2010..In approximately the year 2000, the results of a number of important studies of non-small-cell lung cancer (NSCLC) were published... 
Gefitinib for non-small cell lung cancer patients with liver cirrhosisYoung Hak Kim
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Intern Med 48:1677-9. 2009..Although further studies are needed, a reduced dose of gefitinib might be feasible for patients with liver dysfunction...- A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2Young Hak Kim
Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
Jpn J Clin Oncol 39:576-81. 2009.... - Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapyShuji Ota
Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Lung Cancer 64:98-104. 2009.... - Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancerYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
J Thorac Oncol 5:950-5. 2010..We investigated CSF concentrations of erlotinib and its active metabolite OSI-420... - Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancerKatsuhiro Masago
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507 Japan
Oncol Rep 26:795-803. 2011..We also demonstrated that both IGF1-positive serum and wild-type EGFR were independent poor prognostic factors in patients with non-squamous NSCLC who received gefitinib therapy... - Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapyKatsuhiro Masago
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Clin Lung Cancer 12:56-61. 2011.... - Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusionKatsuhiro Masago
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan
Clin Lung Cancer 12:307-12. 2011..Thus, we investigated the pharmacokinetics (PK) of erlotinib and its active metabolite OSI-420 in non-small-cell lung cancer (NSCLC) of malignant pleural effusion (MPE)... - Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancerYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Japan
Cancer Chemother Pharmacol 70:399-405. 2012..However, there has been no study in which cerebrospinal fluid (CSF) concentrations of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them... - Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugsSeiji Niho
Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwanoha 6-5-1, Kashiwa, Chiba 277-8577, Japan
Jpn J Clin Oncol 36:269-73. 2006.... - Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancerKatsuhiro Masago
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Syogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
Cancer Chemother Pharmacol 67:325-30. 2011.... - Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapyKatsuhiro Masago
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Oncology 84:214-8. 2013..This study aimed to evaluate the association between BCL2 single-nucleotide polymorphisms and survival outcome in advanced non-small cell lung cancer (NSCLC)... - Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapyYoung Hak Kim
Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Cancer 113:2518-23. 2008..To the authors' knowledge, the prognostic factors in recurrent small cell lung cancer (SCLC) patients treated with second-line chemotherapy have not yet been clearly identified to date... - Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancerYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
Lung Cancer 74:98-102. 2011..In contrast, the approved daily dose of gefitinib (250 mg) is only one-third of its MTD. Significantly different adverse events have been associated with gefitinib and erlotinib... - Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancerKatsuhiro Masago
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Syogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
Med Oncol 28:351-6. 2011..The PIC/TAT ratio may become a surrogate marker for treatment with anticoagulants in the future... - Re-challenge chemotherapy for relapsed non-small-cell lung cancerTatsuya Nagano
Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Lung Cancer 69:315-8. 2010..0 months and the 1-year survival rate was 60%. RC led to a significantly better overall survival rate than DOC (p=0.0342). RC could be an active second-line regimen in patients with relapsed NSCLC who responded to first-line chemotherapy... - Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinibKatsuhiro Masago
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto, Japan
Oncology 79:355-62. 2010.... - Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysisYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
J Thorac Oncol 5:601-5. 2010..Thus, we investigated the pharmacokinetics (PK) of erlotinib and its active metabolite OSI-420 in such patients with nonsmall cell lung cancer (NSCLC)... - Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutationYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto, 606 8507, Japan
Cancer Chemother Pharmacol 68:1089-92. 2011..We investigated the plasma and CSF concentrations of erlotinib at each dose as well as the correlation between the plasma and CSF concentrations of erlotinib... - Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinomaYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Cancer 117:819-25. 2011.... - Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancerYoung Hak Kim
Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
Lung Cancer 65:105-11. 2009.... - Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literatureYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
Lung Cancer 77:464-8. 2012..Many patients received corticosteroids during retreatment, but not the one with recurrence of ILD. This may suggest that corticosteroids can prevent recurrence due to their antiinflammatory properties... - Long-term survival in a patient with small-cell lung cancer undergoing hemodialysis who received multiple courses of chemotherapyYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
Jpn J Clin Oncol 41:582-5. 2011.... - Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancerYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Oncol Rep 25:377-82. 2011.... - Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancerYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Clin Lung Cancer 13:304-11. 2012..However, pneumonitis associated with chemotherapy was significantly increased in patients with preexisting ILD, and preexisting ILD is an independent prognostic factor for poorer survival... - Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancerYuichi Sakamori
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Cancer Sci 103:1065-70. 2012..The correlation with clinical response to chemotherapy provides further support for the biologic relevance of these cells in patients' prognosis and highlights the potential use of CEPs as therapeutic targets... - Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancerFengshi Chen
Department of Thoracic Surgery, Kyoto University, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto, 606 8507, Japan
World J Surg 36:2858-64. 2012..The purpose of the present study was to improve the prognosis of patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). To achieve that goal, we performed induction chemoradiotherapy followed by surgery... - Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivoHiroki Nagai
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto 606 8507, Japan
Int J Oncol 41:24-30. 2012..These findings suggest that NO donors, such as NOC-18 and GTN, enhance the anticancer effects of PEM by increasing the RFC1 and FPGS expression and stimulating cGMP signaling pathways in cancer cells... - Two cases of cancer-associated retinopathy combined with small-cell lung cancerYuichi Sakamori
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Jpn J Clin Oncol 41:669-73. 2011..When cancer-associated retinopathy is suspected, a comparatively large quantity of steroids and anticancer treatment should be combined immediately... - Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinomaYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto, 606 8507, Japan
Med Oncol 29:3169-75. 2012..As a consequence, evaluation using a combination of smoking status and vascular-poor area allows us to predict presence of EGFR mutations at a high frequency... - Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinibKatsuhiro Masago
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
Med Oncol 29:1614-21. 2012..We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR... - Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patientsKatsuhiro Masago
Department of Respiratory Medicine, Kyoto University Hospital, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
Int J Clin Oncol 13:442-6. 2008.... - Predictive factors for local recurrence of resected colorectal lung metastasesSatoshi Shiono
Pathology Division, National Cancer Center Research Institute East, Chiba, Japan
Ann Thorac Surg 80:1040-5. 2005.... - Octreotide, a somatostatin analogue, in the treatment of chylothorax associated with idiopathic fibrosing mediastinitisYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
Tohoku J Exp Med 222:51-3. 2010..After discharge, the patient has received octreotide treatment for 6 months without serious adverse events. We suggest octreotide as a treatment option for FM... - Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lungYoung Hak Kim
Pathology Division, National Cancer Center Research Institute East, Chiba, Japan
Clin Cancer Res 10:7311-7. 2004..Thus, this type of adenocarcinoma might be susceptible to postoperative adjuvant treatment with gefitinib... - Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumabYosuke Togashi
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto, 606 8507, Japan
Int J Clin Oncol 16:444-6. 2011..In this article, we present a rare case of non-small cell lung cancer complicated by pulmonary embolism due to internal jugular vein thrombosis associated with bevacizumab... - [A resected case of sclerosing thymoma]Young Hak Kim
Division of Thoracic Oncology, National Cancer Center Hospital East
Nihon Kokyuki Gakkai Zasshi 44:420-3. 2006..Sclerosing thymoma should be taken into account, when only fibrous tissues are obtained by biopsy in patients with anterior mediastinal tumors... - Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?Young Hak Kim
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Case Rep Oncol 4:470-4. 2011..We believe that continuing EGFR-TKI treatment after disease progression should be an option in patients who previously responded to EGFR-TKI under the present circumstances...